The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

摘要

The standard first-line treatment of metastatic non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor is platinum-based chemotherapy, although characterized by great interindividual variation in outcomes. The identification of molecular markers predictive of sensitivity to platinum could thus considerably improve patient care.Preclinical and retrospective analyses indicate that BRCA1 could confer resistance to cisplatin (Ebewe, Pharma co Auckland, NZ) .